Xin Li

Xin Li

Auto-generated profile, based on publicly available information

Xin Li

Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
KGKunj Bihari Gupta
Kunj Bihari Gupta
JGJenny Gao
Jenny Gao
XLXin Li
Xin Li
MTMuthusamy Thangaraju
Muthusamy Thangaraju
Siva S. PandaSiva S. Panda
Siva S. Panda
Bal LokeshwarBal Lokeshwar
Bal Lokeshwar
Background: Oleanolic acid (OA) and Ursolic acid (UA) are bioactive triterpenoids. Reported activities vary with the dose used for testing their activities in vitro. Studies using doses of ≥20 µM showed apoptosis activities in cancer cells. However, reported drug levels in circulation achieved by oral administration of UA and OA are ≤2 µM, thus limiting their use for treatment or delivering a combination treatment. Materials and Methods: The present report demonstrates the efficacy of OA, UA, and OA + UA on tumor cell-specific cytotoxicity at low doses (5 µM to 10 µM) in breast cancer (BrCa) cell lines MCF7 and MDA-MB231. Results: The data show that both OA and UA killed BrCa cells at low doses, but were significantly less toxic to MCF-12A, a non-tumorigenic cell line. Moreover, OA + UA at ≤10 µM was lethal to BrCa cells. Mechanistic studies unraveled the significant absence of apoptosis, but their cytotoxicity was due to the induction of excessive autophagy at a OA + UA dose of 5 µM each. A link to drug-induced cytotoxic autophagy was established by demonstrating a lack of their cytotoxicity by silencing the autophagy-targeting genes (ATGs), which prevented OA-, UA-, or OA + UA-induced cell death. Further, UA or OA + UA treatment of BrCa cells caused an inhibition of PI3 kinase-mediated phosphorylation of Akt/mTOR, the key pathways that regulate cancer cell survival, metabolism, and proliferation. Discussion: Combinations of a PI3K inhibitor (LY294002) with OA, UA, or OA + UA synergistically inhibited BrCa cell survival. Therefore, the dominance of cytotoxic autophagy by inhibiting PI3K-mediated autophagy may be the primary mechanism of PTT-induced anticancer activity in BrCa cells. Conclusion: These results suggest it would be worthwhile testing combined OA and UA in clinical settings.

27 October 2020 in Anticancer Research
Verified
Journal Article
Open access
PDF file
LBLijuan Bai
Lijuan Bai
XLXin Li
Xin Li
XMXiaowei Ma
Xiaowei Ma
RZRui Zhao
Rui Zhao
DWDaqing Wu
Daqing Wu
Background/Aim: Chemoresistance is a major obstacle in the treatment of prostate cancer (PCa). It is imperative to develop novel strategies for overcoming chemoresistance and improving clinical outcomes. We evaluated the in vitro activity and mechanism of action of dihydroergocristine (DHECS), an ergot alkaloid approved for the treatment of dementia, in PCa cells. Materials and Methods: The in vitro effects of DHECS on PCa cell cycle and viability were determined by flow cytometry and colorimetric assay. The effects of DHECS on PCa cell signaling were evaluated by quantitative PCR, western blot analysis and reporter assay. Results: DHECS was effective in inducing cell cycle arrest and apoptosis in human PCa cells. Of particular interest, DHECS demonstrated high potency against chemoresistant PCa cells. At the molecular level, DHECS affected multiple factors implicated in the regulation of cancer cell cycle and programmed cell death, including p53, mouse double minute 2 homolog (MDM2), retinoblastoma protein (RB), p21, E2F transcription factor 1 (E2F1), survivin, myeloid cell leukemia 1 (Mcl-1) and poly ADP ribose polymerase (PARP). Furthermore, DHECS may function through dopamine receptor-mediated effects on 5’-AMP-activated protein kinase (AMPK) and nuclear factor kappa B (NF-ĸB). Conclusion: DHECS has the potential to be repurposed as a novel anticancer agent for the management of chemoresistant PCa.

21 February 2023 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
Baotong ZhangBaotong Zhang
Baotong Zhang
SQSifeng Qu
Sifeng Qu
XLXin Li
Xin Li
XCXinpei Ci
Xinpei Ci
JCJiang Chang
Jiang Chang
Editorial: The development of lethal prostate cancer

9 October 2020
Verified
Conference Paper
Closed access
XLXin Li
Xin Li
Authors: Xin Li 1, 2, Lajos Gera 3, Shumin Zhang 4, Yanhua Chen 2, 5, Lei Lou 6, Lauren Marie Wilson 6, Zhong-Ru Xie 6, Kenza Mamouni 2, Yang Yang 2, 7, Yuhong Du 8, Haian Fu 8, Omer Kucuk 4, 9, Daqing Wu 1, 2, 4, 10 Affiliations: 1 Center for Cancer Research and Therapeutic Development and Department of Biological Sciences, Clark Atlanta University, Atlanta, GA, USA; 2